A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

Genaera

Status and phase: Terminated; Phase 2

Conditions: Macular Degeneration

Treatments: Drug: MSI-1256F (Squalamine Lactate)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00333476

MSI-1256F-212

Details and patient eligibility

About

Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world. AMD presents in two different types - "dry" and the more severe "wet" form. Wet AMD is caused by the growth of abnormal blood vessels in the macula. Squalamine lactate is an investigational drug that may prevent the growth of these abnormal blood vessels. This study will test the safety and efficacy of Squalamine in the treatment of AMD.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult subjects ≥ 50 years of age.
• minimally classic or active occult choroidal neovascularization associated with age-related macular degeneration in one or both eyes.
• baseline best corrected visual acuity score between 35 to 65 letters according to the Early Treatment of Diabetic Retinopathy Study protocol.
• central retinal thickness by optical coherence tomography of > 250 microns.
• lesions > 9 disc areas.
• > 25% fibrosis in the lesion.

Exclusion criteria

• Previous history of triamcinolone, bevacizumab, ranibizumab, or pegaptanib sodium injection therapy in the study eye.
• retinal or optic nerve disease.
• uncontrolled diabetes.
• ongoing malignancy.